COCH earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -0.68. Updated 2026-07-23.
Envoy Medical (COCH) Research Hub
Envoy Medical (COCH) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 0.7402 USD (+7.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.68, market cap 0.01B. This hub links to the full technical, earnings and options research available for COCH.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.7402 USD (+7.23%) |
| 52-week range | 0.6229 USD – 0.85 USD |
| Trend regime | Range |
| 14-day RSI | 60.1 (Bullish) |
| Trailing P/E | -0.68 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for COCH
Covered Call on COCH: how it works, illustrative setup around the real 0.7402 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on COCH: how it works, illustrative setup around the real 0.7402 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on COCH: how it works, illustrative setup around the real 0.7402 USD price, max profit/loss, breakeven and when to use it. Educational.
COCH technical analysis: range, last 0.7402 USD, RSI 60.1, 52w range 0.6229 USD–0.85 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is COCH in?
Envoy Medical (COCH) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is COCH in an uptrend or downtrend?
As of 2026-09-11, COCH is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is COCH's trailing P/E ratio?
COCH's trailing P/E is -0.68, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does COCH next report earnings?
COCH is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.09 USD.